MediPharm Labs Announces Addition to Horizons Marijuana Life Sciences Index ETF

MediPharm Labs Corp. (TSXV: LABS), a specialized, research driven cannabis extraction business licensed under the Cannabis Act, is pleased to announce its addition to the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) (“HMMJ” or “ETF”-RRB-. The addition of MediPharm to the HMMJ Index is a substantial milestone and another significant step in the business ’s evolution as a pioneer in purified cannabis extraction.

HMMJ is an index (or passively managed) ETF, which attempts to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. This index is designed to offer exposure to the performance of a basket of North American publicly recorded life sciences companies with significant business activities in the Marijuana industry. The North American Marijuana Index selects from a current universe of companies that have operations which may include one or more of biopharmaceuticals, medical manufacturing, distribution, bio-products and other ancillary businesses related to the Marijuana industry.

Rebalancing consequently, and of the North American Marijuana Index HMMJ, occurs each calendar quarter. At that stage, all stocks eligible for inclusion are weighted by their market capitalization. However, no stock can exceed a 10% weight of the North American Marijuana Index. The holdings of HMMJ and its current portfolio weights are regularly updated and available at www.HorizonsETFs.com/HMMJ.

About MediPharm Labs Corp..
Founded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a certified producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This specialist focus on cannabis concentrates from its cGMP (current Good Manufacturing Practices) and ISO standard-built clean rooms and critical environments laboratory, allows MediPharm Labs to operate with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil using a competitive advantage. MediPharm Labs is research-driven and concentrated on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, providing integrity-assured cannabis oil to qualified companies for sale under their own brand. Additionally, MediPharm Labs provides raw materials, formulations, packaging and processing for the creation of ready-to-sell innovative derivative products. MediPharm Labs was awarded Start-Up Of The Year at the recent Canadian Cannabis Awards hosted by Lift & Co..

Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also finished its application procedure with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

       
For further information, please contact:     
Laura Lepore, Vice President, Investor Relations & Communications    
Telephone: 705-719-7425 ext 216    
Email: investors@medipharmlabs.com    
       

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”-RRB- within the meaning of the applicable Canadian securities laws. Any announcement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “doesn’t anticipate ”, “is expected”, “anticipates” or “doesn’t expect ”, “aims ”, “funding ”, “scheduled”, “forecasts”, “estimates”, “considers ” & “plans ” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, anticipated GMP certification and the establishment of operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that might cause the actual results and future events to differ materially from those expressed or implied by these forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to get adequate funding; and the delay or failure to receive regulatory approvals. Accordingly, readers shouldn’t place undue reliance on information included in this news release and the forward-looking statements. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other elements, should they change.

Released at Fri, 28 Dec 2018 12:31:05 +0000

Posted in: News

Comments are closed.